Agensys, Inc. and Seattle Genetics have announced interim data from a phase I clinical trial evaluating ASG-5ME for the treatment of castration-resistant prostate cancer (CRPC).
ASG-5ME is, like Seattle Genetics' Adcetris, an antibody-drug conjugate (ADC). It targets the SLC44A4 antigen under co-development by both companies for the treatment of various solid tumors.
Data from the trial was presented at the American Society of Clinical Oncology (ASCO) annual meeting being in Chicago.
In the Phase 1 trial of ASG-5ME in metastatic castration-resistant prostate cancer, 26 patients have been enrolled; their median age is 69.5 years and the median baseline prostate-specific antigen (PSA) level is 82.25.
“It is encouraging to observe these preliminary data with ASG-5ME in prostate cancer, a disease for which late-stage patients need additional therapeutic options,” said Jonathan Drachman, M.D. of Seattle Genetics. “In addition to prostate cancer, our two companies are continuing to evaluate the potential use of ASG-5ME in other solid tumor indications. In parallel, we are collaborating with Agensys to co-develop ASG-22ME, an ADC targeting Nectin-4 for solid tumors.”
“SLC44A4 is an attractive target in prostate cancer and is present in the majority of patients with both localized and metastatic disease,” said Leonard Reyno, M.D. of Agensys. “The current Phase I data demonstrates the tolerability of this antibody drug conjugate and further evaluation of safety and antitumor activity in patients with castration resistant prostate cancer is ongoing.”
Source: Therapeutics Daily
The information provided on CancerTreatment.net is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her health professional. This information is solely for informational purposes and does not constitute the practice of medicine. We encourage all visitors to see a licensed physician or nutritionist if they have any concerns regarding health issues related to diet, personal image and any other topics discussed on this site. Neither the owners or employees of CancerTreatment.net nor the author(s) of site content take responsibility for any possible consequences from any treatment, procedure, exercise, dietary modification, action or application of medication which results from reading this site. Always speak with your primary health care provider before engaging in any form of self treatment. Please see our Legal Statement for further information.
